Survivin and laryngeal carcinoma prognosis: Nuclear localization and expression of splice variants

Histopathology

Volumn 61, Issue 2, 2012, Pages 247-256

  Marioni, Gino ^a   Agostini, Marco ^a,b,c   Bedin, Chiara ^a,c   Blandamura, Stella ^a   Stellini, Edoardo ^a   Favero, Giovanni ^a   Lionello, Marco ^a   Giacomelli, Luciano ^a   Burti, Silvia ^a,b,c   D'Angelo, Edoardo ^a,c   Nitti, Donato ^a   Staffieri, Alberto ^a   De Filippis, Cosimo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Fondazione Istituto di Ricerca Pediatrica Citta della Speranza   (Italy)

Author keywords

Isoforms; Laryngeal carcinoma; P53; Prognosis; Survivin

Indexed keywords

MESSENGER RNA; PROTEIN P53; SURVIVIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL NUCLEUS; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; SEQUENCE ANALYSIS; SURVIVAL TIME; WILD TYPE;

AGED; ALTERNATIVE SPLICING; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864393725     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04217.x     Document Type: Article

References (34)

1. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 2010; 430; 199-205.
2. Kelly RJ, Chavez-Lopez A, Citrin D, Janik JE, Morris JC. Impacting tumor cell fate by targeting the inhibitor of apoptosis protein survivin. Mol. Cancer 2011; 10; 35.
3. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997; 3; 917-921.
4. Li F, Ling X. Survivin study: an update of 'what is the next wave'? J. Cell. Physiol. 2006; 208; 476-486.
5. Marioni G, D'Alessandro E, Bertolin A, Staffieri A. Survivin multifaceted activity in head and neck carcinoma. Current evidence and future therapeutic challenges. Acta. Otolaryngol. (Stockh.) 2010; 130; 4-9.
6. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Antiapoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 351; 882-883.
7. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today 2011; 16; 485-494.
8. Shen Z, Ren Y, Ye D, Guo J, Kang C, Ding H. Significance and relationship between DJ-1 gene and survivin gene expression in laryngeal squamous cell carcinoma. Eur. J. Histochem. 2011; 55; e9.
9. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild-type p53. J. Biol. Chem. 2002; 277; 3247-3257.
10. Mirza A, McGuirk M, Hockenberry TN et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21; 2613-2622.
11. Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 2009; 8; 2708.
12. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat. Rev. 2006; 32; 504-515.
13. Sobin LH, Gospodarowicz MK, Wittekind C eds. TNM classification of malignant tumors, 7th edn. Oxford: Wiley-Blackwell, 2009.
14. Ganci F, Conti S, Fontemaggi G et al. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors. OMICS 2011; 15; 375-381.
15. Marin MC, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 2000; 25; 47-54.
16. Hojo S, Fujita J, Yamadori I et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur. Respir. J. 1998; 12; 1404-1408.
17. Shen Z, Jiang Z, Ye D, Xiao B, Zhang X, Guo J. Growth inhibitory effects of DJ-1-small interfering RNA on laryngeal carcinoma Hep-2 cells. Med. Oncol. 2011; 28; 601-607.
18. Li DW, Gao S, Shen B, Dong P. Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma. Med. Oncol. 2011; 28 (Suppl. 1); 333-340.
19. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res. 2002; 22; 2377-2383.
20. Pizem J, Cör A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 2004; 45; 180-186.
21. Marioni G, Marino F, Bertolin A et al. Expression of the apoptosis inhibitor protein survivin in primary, laryngeal carcinoma and cervical lymph node metastases. Anticancer Res. 2006; 26; 3813-3818.
22. Zhao H, Ren J, Zhuo X, Ye H, Zou J, Liu S. Prognostic significance of survivin and CD44v6 in laryngeal surgical margins. J. Cancer Res. Clin. Oncol. 2008; 134; 1051-1058.
23. García-Fernández E, De Diego JI, Collantes-Bellido E et al. Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications. Histopathology 2011; 58; 368-376.
24. Lippert BM, Knauer SK, Fetz V, Mann W, Stauber RH. Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int. J. Cancer 2007; 121; 1169-1174.
25. De Maria S, Pannone G, Bufo P et al. Survivin gene expression and splicing isoforms in oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2009; 135; 107-116.
26. Qi G, Kudo Y, Ando T et al. Nuclear survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol. 2010; 46; 263-270.
27. Végran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007; 26; 290-297.
28. Ling X, Cheng Q, Black JD, Li F. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J. Biol. Chem. 2007; 282; 27204-27214.
29. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009; 35; 553-562.
30. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008; 14; 5000-5005.
31. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008; 99; 1709-1714.
32. Bang CI, Paik SY, Sun DI, Joo YH, Kim MS. Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. Ann. Otol. Rhinol. Laryngol. 2008; 117; 781-785.
33. Chen X, Luan X, Lei D et al. Suppression of survivin expression by short hairpin RNA induces apoptosis in human laryngeal carcinoma cells. ORL J. Otorhinolaryngol. Relat. Spec. 2008; 70; 168-175.
34. Cheng B, Yang X, Han Z, An L, Liu S. Arsenic trioxide induced the apoptosis of laryngeal cancer via downregulation of survivin mRNA. Auris Nasus Larynx 2008; 35; 95-101.